MedTrace Logo

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

NCT07220863 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-10-24

No results posted yet for this study

Summary

Prospective observational study evaluating the safety and accuracy of Feminai 1.0, an at-home adhesive patch that measures skin temperature and electrical impedance to map each breast. Up to 300 women (ages 25-75) undergoing screening will have one study visit; Feminai results will be compared with mammography and, when available, biopsy to assess sensitivity and negative predictive value. Feminai is investigational, intended to support clinical decision-making, and does not replace standard diagnostic tests.

Conditions

  • Breast Cancer Awareness

Sponsors & Collaborators

  • Feminai

    lead INDUSTRY

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-05
Primary Completion
2026-06-05
Completion
2026-09-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07220863 on ClinicalTrials.gov